Dr. Ye Xinyu, Distinguished Associate Professor and Master’s Supervisor at the Institute of Cell and Gene Technology, Shenzhen University of Advanced Technology. Received a Master’s degree in Biology from Tsinghua University in 2019 and a PhD in Biology from Southern University of Science and Technology in 2023, followed by postdoctoral training at Sun Yat-sen University. Awarded honors including Tsinghua University Outstanding Master’s Thesis, National Scholarship for PhD Students at Southern University of Science and Technology, and Guangdong Outstanding Student; selected for the National Postdoctoral Program (Category B).

Dr. Ye’s research focuses on the tumor microenvironment and tumor immunotherapy, with over 10 papers published in internationally renowned journals such asJournal of Hematology & Oncology(IF: 40.4),ACS Nano(IF: 16), andJournal of Controlled Release(IF: 11.5), including 5 as first or co-first author. His papers have received over 800 total citations, with an H-index of 8.

2019.09-2023.06, PhD in Biology, Southern University of Science and Technology

2016.09-2019.06, Master’s Degree in Biology, Tsinghua University

2012.09-2016.06, Bachelor’s Degree in Biotechnology, Weifang Medical College (Shandong Second Medical University)

2025.11–present, Distinguished Associate Professor, Institute of Cell and Gene Technology, Shenzhen University of Advanced Technology

2023.10-2025.10, Postdoctoral Fellow in Basic Medicine, Sun Yat-sen University

Therapy-induced senescence (TIS) plays a “double-edged sword” role in tumor therapy, capable of inhibiting tumor growth while potentially promoting tumor progression. Given this dual role of TIS, our research focuses on deeply elucidating the molecular mechanisms regulating tumor therapeutic outcomes, clarifying the underlying logic of its tumor-suppressive and tumor-promoting effects, systematically identifying key regulatory factors, and developing precise intervention strategies on this basis—aiming to enhance the anti-tumor function of TIS while effectively blocking or suppressing its tumor-promoting effects, ultimately achieving “maximizing strengths and minimizing weaknesses” to improve overall tumor therapy efficacy.

The research is conducted around the following two directions:

(1) Identification of novel targets driving TIS-related tumor therapy resistance

Based on clinical samples, multiple mouse models, and in vitro cell systems, we will systematically investigate the role and mechanisms of cellular senescence induced by treatments such as radiotherapy and chemotherapy (including in tumor cells, macrophages, T cells, etc.) in tumor therapy resistance. Emphasis will be placed on how senescent cells regulate the immune microenvironment through SASP, promote stemness, or enhance DNA repair capacity, thereby identifying key molecules amenable to targeted intervention and providing new ideas for precise regulation of tumor senescence and personalized therapy.

(2) Development of innovative monocyte-based cell therapies

Currently, cell therapies represented by CAR-T and CAR-NK have achieved significant breakthroughs in hematological tumors and other fields. However, solid tumor treatment still faces challenges such as microenvironment suppression and insufficient infiltration. Monocytes are widely sourced, easily accessible, possess natural tumor-homing ability and high plasticity, and can directionally differentiate into macrophages or dendritic cells in the tumor microenvironment, exerting powerful antigen presentation and immune regulation functions. In the future, we will integrate cutting-edge technologies such as immunology, synthetic biology, and AI-driven protein design to construct a precisely regulatable monocyte therapy platform, aiming to actively reshape the immunosuppressive microenvironment, activate endogenous anti-tumor immune responses, and provide next-generation cell therapy strategies for solid tumor treatment.

Research Projects:

1. China Postdoctoral Science Foundation, General Project, 2024-07-01 to 2025-12-31, CNY 80,000, Completed, Principal Investigator.

2. National Natural Science Foundation of China, General Project, 2020-01-01 to 2023-12-31, CNY 510,000, Ongoing, Participant.

3. National Natural Science Foundation of China, General Project, 2020-01-01 to 2023-12-31, CNY 550,000, Ongoing, Participant.

Representative Achievements

1.Ye Xinyu*, Huang X*, Fu X, Zhang X, Lin R, Zhang W, Zhang J#, Lu Y#. Myeloid-like tumor hybrid cells in bonemarrow promote progression of prostate cancer bone metastasis. J Hematol Oncol. 2023 May 3;16(1):46. (Firstauthor, JCR Q1, IF:40.4)

2.Ye Xinyu*, Liu J, Quan R, Lu Y*, Zhang J*. DKK1 affects survival of patients with head and neck squamous cellcarcinoma by inducing resistance to radiotherapy and immunotherapy. Radiother Oncol. 2023 Apr;181:109485. (Firstauthor, JCR Q1, IF:5.3)

3.Ye Xinyu*, Liang X*, Chen Q, Miao Q, Chen X, Zhang X#, Mei L#. Surgical Tumor-Derived PersonalizedPhotothermal Vaccine Formulation for Cancer Immunotherapy. ACS Nano. 2019 Mar 26;13(3):2956-2968. (Firstauthor, JCR Q1, IF:16)

4. Liang X*,Ye Xinyu*, Wang C, Xing C, Miao Q, Xie Z, Chen X, Zhang X, Zhang H#, Mei L#. Photothermal cancerimmunotherapy by erythrocyte membrane-coated black phosphorus formulation. J Control Release. 2019 Feb28;296:150-161.(Co-first author, JCR Q1, IF:11.5)

5. Wang C*,Ye Xinyu*, Zhao Y, Bai L, He Z, Tong Q, Xie X, Zhu H, Cai D, Zhou Y, Lu B, Wei Y, Mei L#, Xie D#, Wang M#. Cryogenic 3D printing of porous scaffolds for in situ delivery of 2D black phosphorus nanosheets, doxorubicin hydrochloride and osteogenic peptide for treating tumor resection-induced bone defects. Biofabrication. 2020 Apr 9;12(3):035004. (Co-first author, JCR Q1, IF:8)

窗体底端